Jun Do Youn, Kim Hyejin, Jang Won Young, Lee Ji Young, Fukui Kiyoshi, Kim Young Ho
Laboratory of Immunobiology, School of Life Sciences and Biotechnology, College of Natural Sciences, Kyungpook National University, Daegu, Korea.
Institute of Life Science and Biotechnology, Kyungpook National University, Daegu, Korea.
PLoS One. 2017 May 2;12(5):e0176544. doi: 10.1371/journal.pone.0176544. eCollection 2017.
Human lysosomal-associated protein multispanning membrane 5 (LAPTM5) was identified by an ordered differential display-polymerase chain reaction (ODD-PCR) as an up-regulated cDNA fragment during 12-O-tetradecanoylphorbol 13-acetate (TPA)-induced differentiation of U937 cells into monocytes/macrophages. After TPA-treatment, the levels of LAPTM5 mRNA and protein increased and reached a maximum at 18-36 h. In healthy human tissues, LAPTM5 mRNA was expressed at high levels in hematopoietic cells and tissues, at low levels in the lung and fetal liver, and was not detected in other non-hematopoietic tissues. LAPTM5 mRNA was detected in immature malignant cells of myeloid lineage, such as K562, HL-60, U937, and THP-1 cells, and in unstimulated peripheral T cells, but was absent or barely detectable in lymphoid malignant or non-hematopoietic malignant cells. The LAPTM5 level in HL-60 cells increased more significantly during TPA-induced monocyte/macrophage differentiation than during DMSO-induced granulocyte differentiation. Ectopic expression of GFP-LAPTM5 or LAPTM5 in HeLa cells exhibited the localization of LAPTM5 to the lysosome. In HeLa cells overexpressing LAPTM5, the Mcl-1 and Bid levels declined markedly and apoptosis was induced via Bak activation, Δψm loss, activation of caspase-9, -8 and -3, and PARP degradation without accompanying necrosis. However, these LAPTM5-induced apoptotic events except for the decline of Bid level were completely abrogated by concomitant overexpression of Mcl-1. The pan-caspase inhibitor (z-VAD-fmk) could suppress the LAPTM5-induced apoptotic sub-G1 peak by ~40% but failed to block the induced Δψm loss, whereas the broad-range inhibitor of cathepsins (Cathepsin Inhibitor I) could suppress the LAPTM5-induced apoptotic sub-G1 peak and Δψm loss, by ~22% and ~23%, respectively, suggesting that the LAPTM5-mediated Δψm loss was exerted at least in part in a cathepsin-dependent manner. Together, these results demonstrate that ectopic overexpression of LAPTM5 in HeLa cells induced apoptosis via cleavage of Mcl-1 and Bid by a LAPTM5-associated lysosomal pathway, and subsequent activation of the mitochondria-dependent caspase cascade.
人类溶酶体相关蛋白多跨膜蛋白5(LAPTM5)通过有序差异显示聚合酶链反应(ODD-PCR)被鉴定为在12-O-十四烷酰佛波醇13-乙酸酯(TPA)诱导U937细胞分化为单核细胞/巨噬细胞过程中上调的cDNA片段。TPA处理后,LAPTM5 mRNA和蛋白水平升高,并在18 - 36小时达到峰值。在健康人体组织中,LAPTM5 mRNA在造血细胞和组织中高水平表达,在肺和胎肝中低水平表达,在其他非造血组织中未检测到。在髓系谱系的未成熟恶性细胞如K562、HL-60、U937和THP-1细胞以及未刺激的外周T细胞中检测到LAPTM5 mRNA,但在淋巴恶性或非造血恶性细胞中不存在或几乎检测不到。HL-60细胞中LAPTM5水平在TPA诱导的单核细胞/巨噬细胞分化过程中比在二甲基亚砜(DMSO)诱导的粒细胞分化过程中升高更显著。GFP-LAPTM5或LAPTM5在HeLa细胞中的异位表达显示LAPTM5定位于溶酶体。在过表达LAPTM5的HeLa细胞中,Mcl-1和Bid水平显著下降,并通过Bak激活、线粒体膜电位(Δψm)丧失、caspase-9、-8和-3激活以及PARP降解诱导凋亡,且无伴随坏死。然而,除Bid水平下降外,这些LAPTM5诱导的凋亡事件通过同时过表达Mcl-1完全消除。泛半胱天冬酶抑制剂(z-VAD-fmk)可将LAPTM5诱导的凋亡亚G1峰抑制约40%,但未能阻断诱导的Δψm丧失,而组织蛋白酶广谱抑制剂(组织蛋白酶抑制剂I)可分别将LAPTM5诱导的凋亡亚G1峰和Δψm丧失抑制约22%和约23%,表明LAPTM5介导的Δψm丧失至少部分以组织蛋白酶依赖性方式发挥作用。总之,这些结果表明,LAPTM5在HeLa细胞中的异位过表达通过LAPTM5相关的溶酶体途径切割Mcl-1和Bid,随后激活线粒体依赖性半胱天冬酶级联反应诱导凋亡。